Metoprolol succinate + doxazosin ( DrugBank: Metoprolol, Doxazosin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 57 | Idiopathic dilated cardiomyopathy | 1 |
57. Idiopathic dilated cardiomyopathy
Clinical trials : 12 / Drugs : 25 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 34
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01798992 (ClinicalTrials.gov) | September 2000 | 22/2/2013 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart | Idiopathic Dilated Cardiomyopathy | Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin | University of Colorado, Denver | National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca | Completed | 18 Years | N/A | All | 56 | Phase 4 | United States |